Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells 289,024 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 289,024 shares of Adaptive Biotechnologies stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $15.82, for a total value of $4,572,359.68. Following the completion of the sale, the chief executive officer owned 1,987,330 shares of the company’s stock, valued at $31,439,560.60. This trade represents a 12.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Adaptive Biotechnologies Stock Down 0.2%

Shares of ADPT stock traded down $0.04 during trading hours on Tuesday, hitting $16.08. 1,777,424 shares of the company were exchanged, compared to its average volume of 1,733,053. The firm has a fifty day moving average of $16.85 and a 200 day moving average of $15.79. Adaptive Biotechnologies Corporation has a 1 year low of $6.26 and a 1 year high of $20.76. The firm has a market cap of $2.48 billion, a PE ratio of -40.20 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same period in the previous year, the firm earned ($0.23) earnings per share. Adaptive Biotechnologies’s revenue was up 51.0% compared to the same quarter last year. Analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ADPT. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. JPMorgan Chase & Co. upped their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 6th. BTIG Research raised their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Guggenheim boosted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in Adaptive Biotechnologies during the 4th quarter worth approximately $28,000. T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at approximately $51,000. Invesco Ltd. grew its position in shares of Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after buying an additional 2,216,595 shares in the last quarter. Corient Private Wealth LLC increased its stake in shares of Adaptive Biotechnologies by 3.4% in the fourth quarter. Corient Private Wealth LLC now owns 71,908 shares of the company’s stock worth $1,168,000 after buying an additional 2,347 shares during the last quarter. Finally, Strive Financial Group LLC bought a new stake in shares of Adaptive Biotechnologies in the fourth quarter worth $52,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.